Microscopic colitis

Other biological agents

Other biological agents may be recommended for the treatment of microscopic colitis, including ustekinumab (an interleukin-12/23 inhibitor) and tofacitinib (a Janus kinase inhibitor). In case reports, the combination of ustekinumab and azathioprine was successful in treating a patient with severe microscopic colitis refractory to oral budesonide, and tofacitinib resulted in persistent and histological remission in a patient with refractory microscopic colitis and concomitant coeliac disease.[79]Abughazaleh S, Glassner K, Wilhite A, et al. A stellar case of stelara in the treatment of lymphocytic colitis. American Journal of Gastroenterology. 2019;114:S1154. https://journals.lww.com/ajg/Abstract/2019/10001/2063_A_Stellar_Case_of_Stelara_in_the_Treatment_of.2064.aspx [80]Lenfant M, De Hertogh G, Verstockt B. Tofacitinib for celiac disease and microscopic colitis: killing two birds with one stone. Acta Gastroenterol Belg. 2023 Apr-Jun;86(2):374-6. https://www.ageb.be/Articles/Volume%2086%20(2023)/Fasc2/19-Lenfant.pdf http://www.ncbi.nlm.nih.gov/pubmed/37428175?tool=bestpractice.com These drugs are approved for the treatment of ulcerative colitis, but are not recommended by guidelines for use in microscopic colitis as yet.